Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.

ABSTRACT:

Introduction

Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across multiple cancer types. The recommended starting doses for lenvatinib differ across cancer types and indications based on whether it is used as monotherapy or as combination therapy.

Areas covered

This review covers clinical trials that established the dosing paradigm and efficacy of lenvatinib and defined its adverse-event profile as a monotherapy; or in combination with the mTOR inhibitor, everolimus; or the anti-PD-1 antibody, pembrolizumab; and/or chemotherapy.

Expert opinion

Lenvatinib has been established as standard-of-care either as a monotherapy or in combination with other anticancer agents for the treatment of radioiodine-refractory

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC9484451 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature